AR068332A1 - Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne - Google Patents
Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenneInfo
- Publication number
- AR068332A1 AR068332A1 ARP080103355A ARP080103355A AR068332A1 AR 068332 A1 AR068332 A1 AR 068332A1 AR P080103355 A ARP080103355 A AR P080103355A AR P080103355 A ARP080103355 A AR P080103355A AR 068332 A1 AR068332 A1 AR 068332A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- agent
- aryl
- compound
- formula
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 5
- 239000000890 drug combination Substances 0.000 title 1
- 210000003205 muscle Anatomy 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 16
- 150000001875 compounds Chemical class 0.000 abstract 12
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 238000011321 prophylaxis Methods 0.000 abstract 5
- 125000003107 substituted aryl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 4
- 206010006895 Cachexia Diseases 0.000 abstract 3
- 239000003246 corticosteroid Substances 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003435 aroyl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000001589 carboacyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 1
- KSGCNXAZROJSNW-UHFFFAOYSA-N 5-ethylsulfonyl-2-naphthalen-2-yl-1,3-benzoxazole Chemical compound C1=CC=CC2=CC(C=3OC4=CC=C(C=C4N=3)S(=O)(=O)CC)=CC=C21 KSGCNXAZROJSNW-UHFFFAOYSA-N 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 102000001039 Dystrophin Human genes 0.000 abstract 1
- 108010069091 Dystrophin Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000004472 Myostatin Human genes 0.000 abstract 1
- 108010056852 Myostatin Proteins 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 102000011856 Utrophin Human genes 0.000 abstract 1
- 108010075653 Utrophin Proteins 0.000 abstract 1
- 238000005054 agglomeration Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 239000003263 anabolic agent Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 239000012752 auxiliary agent Substances 0.000 abstract 1
- 239000002876 beta blocker Substances 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 229960003624 creatine Drugs 0.000 abstract 1
- 239000006046 creatine Substances 0.000 abstract 1
- 238000004132 cross linking Methods 0.000 abstract 1
- 229960001145 deflazacort Drugs 0.000 abstract 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001483 mobilizing effect Effects 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229960005205 prednisolone Drugs 0.000 abstract 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract 1
- 229960004618 prednisone Drugs 0.000 abstract 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- 125000005000 thioaryl group Chemical group 0.000 abstract 1
- 230000003827 upregulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Reivindicacion 1: Una combinacion caracterizada porque comprende (o consiste esencialmente en) un agente auxiliar y un compuesto de la formula (1): en donde A1, A2, A3 y A4, los cuáles pueden ser iguales o diferentes, representan N o CR1, X es un grupo divalente seleccionado entre O, S(O), C=W, NR4, NC(=O)R5 y CR6R7, W es O, S, NR20, Y es N o CR8, uno de R4, R5, R6, R8, R9 y NR20 representa -L-R3, en donde L es una union simple o un grupo puente, adicionalmente, R1: R3 - R9, los cuales pueden ser iguales o diferentes, en forma independiente representan hidrogeno o un sustituyente y R20 representa hidrogeno, hidroxilo, alquilo opcionalmente sustituido con arilo, alcoxi opcionalmente sustituido con arilo, arilo, EN, alcoxi opcionalmente sustituido, ariloxi opcionalmente sustituido, alcanoilo opcionalmente sustituido, aroilo opcionalmente sustituido, NO2, NR30R31, en donde R30 .y R31, los cuales pueden ser iguales o diferentes, representan hidrogeno, alquilo opcionalmente sustituido o arilo opcionalmente sustituido; adicionalmente, uno de R30 y R31 puede representar alcanoilo opcionalmente sustituido o aroilo opcionalmente sustituido, n representa un entero entre 0 y 2, adicionalmente, cuando un par adyacente de A1 - A4 cada uno representa CR1, luego los átomos de carbono adyacentes, junto con sus sustituyentes pueden formar un anillo B, cuando X es CR6R7, R6 y R7, junto con el carbono átomo al cual están unidos pueden formar un anillo C, o una sal aceptable para uso farmacéutico del mismo, opcionalmente para el tratamiento terapéutico o profiláctico de Distrofia muscular de Duchenne, Distrofia muscular de Becker o caquexia. Reivindicacion 2: La combinacion de acuerdo con la reivindicacion 1, caracterizada porque R3 en el compuesto de la formula 1 representa alquilo, alcoxi o arilo, cada uno opcionalmente sustituido con uno a tres sustituyentes, R2, los cuales pueden ser iguales o diferentes. Reivindicacion 3: La combinacion de acuerdo con la reivindicacion 1, caracterizada porque L es una union simple y R3 representa: tioalquilo opcionalmente sustituido con alquilo o arilo opcionalmente sustituido, tioarilo, en donde el arilo se sustituye opcionalmente, arilo opcionalmente sustituido, hidroxilo, NO2, EN, NR10R11, halogeno, SO2R12, NR13SO2R14, C(=W)R16, OC(=W)NR10R11, NR015C(=W)R17, R10, R11, R12, R13, R14, R15, R16 y R17, los cuales pueden ser iguales o diferentes, representan hidrogeno, alquilo opcionalmente sustituido con arilo opcionalmente sustituido, arilo opcionalmente sustituido, adicionalmente, NR10R11 junto con el nitrogeno al cual están unidos pueden formar un anillo, R12 puede tener el mismo significado que NR10R11, cuando R17 representa NR10R11, ese NR10R11 puede representar hidrogeno, CO alquilo y CO arilo opcionalmente sustituido, R16 y R17, los cuales pueden ser iguales o diferentes, cada uno puede representar alquilo sustituido con uno o más de halogeno, alcoxi arilo opcionalmente sustituido o arilo opcionalmente sustituido, ariloxi opcionalmente sustituido, arilo o NR10R11, y cuando R16 o R17 representa NR10R11, uno de R10 y R11, puede representar adicionalmente CO alquilo opcionalmente sustituido o CO arilo opcionalmente sustituido, y adicionalmente a las definiciones compartidas con R17, R16 puede representar hidroxi. Reivindicacion 39: La combinacion de cualquiera de las reivindicaciones 1 a 38, caracterizada porque el agente suplementario y el compuesto de la formula (1) están asociados físicamente. Reivindicacion 40: La combinacion de la reivindicacion 39, caracterizada porque el agente suplementario y el compuesto de la formula (1) están: (a) mezclados (por ejemplo dentro de la misma unidad de dosificacion): (b) asociados químicamente/fisicoquímicamente (por ejemplo mediante entrecruzamiento, aglomeracion molecular o union a un grupo vehículo comun): (c) envasados químicamente/fisicoquímicamente juntos (por ejemplo, dispuestos sobre o dentro de vesículas lipídicas o partículas (por ejemplo micro o nanopartículas) o gotitas de emulsion); (d) sin mezclar pero envasados juntos o presentados juntos (por ejemplo como parte de un arreglo de dosis unitarias). Reivindicacion 41: La combinacion de cualquiera de las reivindicaciones 1 a 39, caracterizada porque el agente suplementario y el compuesto de la formula (1) están asociados en forma no física. Reivindicacion 43. Un envase farmacéutico, conjunto de componentes o envase para paciente caracterizado porque comprende una combinacion como se define en cualquiera de las reivindicaciones 1 a 42. Reivindicacion 44: Un agente suplementario caracterizado porque es para usar en una terapia combinada con un compuesto de la formula (1) como se define en cualquiera de las reivindicaciones 1 a 39. Reivindicacion 45: Un compuesto de la formula (1) definido en cualquiera de las reivindicaciones 1 a 39, caracterizado porque es para usar en una terapia combinada con un agente suplementario. Reivindicacion 47. Uso de un agente suplementario caracterizado porque es para la elaboracion de un medicamento para usar en el tratamiento o profilaxis (por ejemplo el tratamiento terapéutico y/o profiláctico de la distrofia muscular de Duchenne, la distrofia muscular de Becker o caquexia) en un paciente sometido a tratamiento con un compuesto de la formula (1) definido en cualquiera de las reivindicaciones 1 a 39. Reivindicacion 48: Uso de un compuesto de la formula (1) definido en cualquiera de las reivindicaciones 1 a 39, caracterizada porque es para la elaboracion de un medicamento para usar en el tratamiento o profilaxis (por ejemplo el tratamiento terapéutico y/o profiláctico de la distrofia muscular de Duchenne, la distrofia muscular de Becker o caquexia) en un paciente sometido a tratamiento con un agente suplementario. Reivindicacion 49: La combinacion de cualquiera de las reivindicaciones precedentes, caracterizada porque el agente suplementario se selecciona entre: (a) un agente antiinflamatorio; (b) un inhibidor de proteasa; (c) un antagonista de miostatina; (d) una citoquina o agente movilizante; (e) un corticoesteroide; (f) un esteroide anabolico; (g) un antagonista de TGF-beta; (h) un antioxidante o agente de soporte mitocondrial; (1) una agente de potenciacion de expresion de distrofina; (j) un agente de reemplazo/reparacion génica; (k) una composicion a base de células; (l) creatina; (m) un agente anti osteoporosico; (n) un agente suplementario para la regulacion positiva de utrofina; (o) un modulador de senalizacion por GMPc; y (p) una combinacion de dos o más de las clases antes mencionadas entre (a) y (o). Reivindicacion 50: La invencion de cualquiera de las reivindicaciones precedentes, caracterizada porque el compuesto de la formula (1) es el compuesto numero 390 de la Tabla 1 que es el 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol. Reivindicacion 51: La invencion de la reivindicacion 50, caracterizada porque el agente suplementario es un corticoesteroide. Reivindicacion 52: La invencion de la reivindicacion 51, caracterizada porque el corticoesteroide se selecciona entre prednisona, prednisolona o deflazacort. Reivindicacion 53: Un proceso para producir una combinacion definida en cualquiera de las reivindicaciones precedentes, caracterizado porque comprende el paso de combinar un compuesto de la formula (1) definido en cualquiera de las reivindicaciones precedentes, con uno o más agente(s) suplementario(s) (como se define en la presente documentacion).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0715088A GB0715088D0 (en) | 2007-08-03 | 2007-08-03 | Drug combinations for the treatment of duchenne muscular dystrophy |
| GB0807216A GB0807216D0 (en) | 2008-04-21 | 2008-04-21 | Drug combination for the treatment of duchenne muscular dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068332A1 true AR068332A1 (es) | 2009-11-11 |
Family
ID=40019245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103355A AR068332A1 (es) | 2007-08-03 | 2008-08-01 | Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8501713B2 (es) |
| EP (2) | EP2170396B1 (es) |
| JP (1) | JP2010535708A (es) |
| CN (1) | CN101678107A (es) |
| AR (1) | AR068332A1 (es) |
| AU (1) | AU2008285289A1 (es) |
| BR (1) | BRPI0811317A2 (es) |
| CA (1) | CA2685540C (es) |
| CL (1) | CL2008002279A1 (es) |
| CY (1) | CY1118700T1 (es) |
| DK (1) | DK2170396T3 (es) |
| ES (1) | ES2617957T3 (es) |
| HR (1) | HRP20170313T1 (es) |
| HU (1) | HUE033195T2 (es) |
| LT (1) | LT2170396T (es) |
| MX (1) | MX2009012558A (es) |
| PE (1) | PE20090510A1 (es) |
| PL (1) | PL2170396T3 (es) |
| PT (1) | PT2170396T (es) |
| RS (1) | RS55735B1 (es) |
| SI (1) | SI2170396T1 (es) |
| TW (1) | TW200911237A (es) |
| WO (1) | WO2009019504A1 (es) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012627A2 (en) | 2004-07-23 | 2006-02-02 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| PT1973559E (pt) | 2005-11-23 | 2013-02-19 | Acceleron Pharma Inc | Antagonistas de activina-actriia e utilizações para promover o crescimento ósseo |
| US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| SG173312A1 (en) * | 2006-06-23 | 2011-08-29 | Abbott Lab | Cyclopropyl amine derivatives as histamin h3 receptor modulators |
| EP2468290B1 (en) | 2006-12-18 | 2015-04-01 | Acceleron Pharma, Inc. | Activin-ActRII Antagonists for use in treating anemia |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CN103920139B (zh) | 2007-02-01 | 2018-02-02 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途 |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| TWI667038B (zh) | 2007-02-09 | 2019-08-01 | 美商艾瑟勒朗法瑪公司 | 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途 |
| RS55735B1 (sr) | 2007-08-03 | 2017-07-31 | Summit (Oxford) Ltd | Kombinacije lekova za lečenje dišenove mišićne distrofije |
| US7960343B2 (en) | 2007-09-18 | 2011-06-14 | Acceleron Pharma Inc. | Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion |
| TWI748373B (zh) | 2008-08-14 | 2021-12-01 | 美商艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| CA2737694C (en) | 2008-09-26 | 2013-07-02 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| EP2352374B1 (en) | 2008-10-29 | 2014-09-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
| US8138142B2 (en) | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
| WO2010108187A2 (en) * | 2009-03-20 | 2010-09-23 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| GB0905667D0 (en) * | 2009-04-02 | 2009-05-20 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| KR20210034684A (ko) | 2009-06-12 | 2021-03-30 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| JP5540640B2 (ja) | 2009-10-07 | 2014-07-02 | 住友化学株式会社 | 複素環化合物及びその有害節足動物防除用途 |
| KR101194995B1 (ko) * | 2009-10-14 | 2012-10-29 | 주식회사 이큐스앤자루 | 신규한 2-페닐-벤즈이미다졸 또는 2-페닐-벤즈옥사졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항바이러스용 약학적 조성물 |
| JP6267425B2 (ja) | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ， インコーポレイテッド | 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用 |
| AU2011211744B2 (en) * | 2010-02-03 | 2015-06-18 | Microbial Chemistry Research Foundation | Read through inducer, and therapeutic agent for nonsense-mutation-type genetic diseases |
| WO2011099832A2 (en) * | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| JP5544940B2 (ja) * | 2010-03-10 | 2014-07-09 | Ｊｎｃ株式会社 | インドール環を有する化合物、液晶組成物、及び液晶表示素子 |
| US20130090371A1 (en) * | 2010-04-20 | 2013-04-11 | President And Fellows Of Harvard College | Methods and compositions for inhibition of beta2-adrenergic receptor degradation |
| US8686048B2 (en) * | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
| CN103037694B (zh) | 2010-06-23 | 2014-08-13 | 住友化学株式会社 | 防治有害节肢动物的组合物和杂环化合物 |
| CN103096928A (zh) * | 2010-06-28 | 2013-05-08 | 萩原正敏 | 遗传性疾病的预防/改善剂 |
| WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| KR20130132824A (ko) | 2010-11-08 | 2013-12-05 | 악셀레론 파마 인코포레이티드 | Actriia 결합제 및 이의 용도 |
| WO2012102937A2 (en) * | 2011-01-25 | 2012-08-02 | Irm Llc | Compounds that expand hematopoietic stem cells |
| CN102617478B (zh) * | 2011-01-31 | 2015-07-15 | 华东理工大学 | 苯并咪唑、噁唑和噻唑衍生物的合成及其应用 |
| CN103748085A (zh) | 2011-06-09 | 2014-04-23 | 诺华股份有限公司 | 杂环磺酰胺衍生物 |
| US20140080896A1 (en) * | 2011-08-30 | 2014-03-20 | The Regents Of The University Of California | Identification of small molecules that facilitate therapeutic exon skipping |
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| AP2014007595A0 (en) * | 2011-09-30 | 2014-04-30 | Kineta Inc | Anti-viral compounds |
| WO2013120040A1 (en) * | 2012-02-10 | 2013-08-15 | Children's Medical Center Corporation | Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy |
| CN104245694B (zh) | 2012-03-06 | 2017-11-03 | 特殊化合物服务有限公司 | 具有治疗活性的氨基亚甲基吡唑啉酮 |
| EP2636673A1 (en) * | 2012-03-06 | 2013-09-11 | Compound Handling B.V. | Aminomethylene pyrazolones with therapeutic activity |
| GB201208178D0 (en) | 2012-05-10 | 2012-06-20 | Summit Corp Plc | Pharmaceutical composition for the treatment of duchenne muscular dystrophy |
| MX2015004500A (es) | 2012-10-17 | 2015-07-06 | Hoffmann La Roche | Derivados de 6-aminoindol como antagonistas del canal receptor de potencial transitorio (trp). |
| MX389254B (es) | 2012-11-02 | 2025-03-20 | Celgene Corp | Antagonistas de activina-actrii y usos para tratar trastornos oseos y otros. |
| BR112015023031A2 (pt) | 2013-03-15 | 2017-07-18 | Abbott Lab | métodos de conservação e melhoria da função múscular |
| US20160067246A1 (en) * | 2013-04-19 | 2016-03-10 | Cedars-Sinai Medical Center | Use of phosphodiesterase 5a inhibitors for the treatment of muscular dystrophy |
| WO2014190250A1 (en) * | 2013-05-23 | 2014-11-27 | The Johns Hopkins University | Activators of soluable guanylate cyclase and their use in treatment of duchenne muscular dystrophy and related disease |
| RU2681537C2 (ru) * | 2014-04-14 | 2019-03-07 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение |
| AP2017009674A0 (en) | 2014-06-13 | 2017-01-31 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| GB201412010D0 (en) | 2014-07-04 | 2014-08-20 | Summit Corp Plc | Treatment of hypertransaminasemia |
| US9353093B2 (en) | 2014-10-07 | 2016-05-31 | Allergan, Inc. | Indole-1-carboxamides as kinase inhibitors |
| US9403803B2 (en) * | 2014-10-08 | 2016-08-02 | Allergan, Inc. | Indole-3-carboxamides as kinase inhibitors |
| US9371314B2 (en) | 2014-10-09 | 2016-06-21 | Allergan, Inc. | Pyridyl benzothiophenes as kinase inhibitors |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| ES2946160T3 (es) | 2014-12-03 | 2023-07-13 | Celgene Corp | Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico |
| US10399966B2 (en) | 2016-01-21 | 2019-09-03 | University Of Washington | Compounds for treatment of trypanosomes and neurological pathogens and uses thereof |
| CN105712950B (zh) * | 2016-01-27 | 2019-05-21 | 中国科学院化学研究所 | 基于苯并噻唑的酰胺类化合物及其制备方法和应用 |
| EP3431472B1 (en) * | 2016-03-17 | 2023-05-03 | Checkmate Therapeutics Inc. | Novel compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same |
| KR20190026647A (ko) * | 2016-03-30 | 2019-03-13 | 서밋 (옥스포드) 리미티드 | 뒤쉔 근육 영양장애의 치료용 조성물 |
| RS65335B1 (sr) | 2018-10-05 | 2024-04-30 | Annapurna Bio Inc | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj |
| US12473266B2 (en) | 2018-10-10 | 2025-11-18 | Albert Einstein College Of Medicine | Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators |
| CN109400536A (zh) * | 2018-12-21 | 2019-03-01 | 东华大学 | 一种n取代苯并咪唑二胺及其制备方法 |
| KR102658031B1 (ko) * | 2018-12-27 | 2024-04-18 | 제이투에이치바이오텍 (주) | 근이영양증의 치료 또는 예방에 유용한 화합물 및 이들의 의약 용도의 치료, 개선 또는 예방용 유도체 |
| CN109730999B (zh) * | 2018-12-28 | 2021-12-24 | 中山大学 | 噻唑苯甲酰胺衍生在制备抗骨质疏松、抗骨关节炎药物中的应用 |
| TW202043205A (zh) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Menin-mll相互作用之抑制劑 |
| WO2020142557A1 (en) | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Irreversible inhibitors of menin-mll interaction |
| CN109912424B (zh) * | 2019-03-01 | 2020-08-07 | 浙江大学 | 硝基苯胺类物质水解成酚的方法 |
| KR20220050126A (ko) * | 2019-06-12 | 2022-04-22 | 티엠이엠16에이 리미티드 | 호흡기 질환을 치료하기 위한 화합물 |
| CA3162227A1 (en) * | 2019-12-16 | 2021-06-24 | David Scott Grierson | Antiviral compounds, compositions and methods of use |
| EP4384179A1 (en) | 2021-08-11 | 2024-06-19 | Biomea Fusion, Inc. | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
| CN119816500A (zh) | 2021-08-20 | 2025-04-11 | 拜欧米富士恩公司 | 用于治疗癌症的不可逆menin-MLL抑制剂N-[4-[4-(4-吗啉基)-7H-吡咯并[2,3-d]嘧啶-6-基]苯基]-4-[[3(R)-[(1-氧代-2-丙烯-1-基)氨基]-1-哌啶基]甲基]-2-吡啶甲酰胺的结晶形式 |
| CN116262744A (zh) * | 2021-12-13 | 2023-06-16 | 复旦大学 | 用于α-突触核蛋白聚集体成像的小分子探针 |
| CA3242198A1 (en) * | 2021-12-27 | 2023-07-06 | Astellas Pharma Inc. | Substituted quinoline derivative |
| WO2024155710A1 (en) | 2023-01-18 | 2024-07-25 | Biomea Fusion, Inc. | Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction |
| WO2025189127A1 (en) * | 2024-03-08 | 2025-09-12 | Automera PTE. LTD | Benzofuran derivatives for targeting autophagy |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE628696A (es) * | 1962-02-21 | |||
| BE637389A (es) | 1962-09-13 | |||
| US3993659A (en) * | 1971-08-10 | 1976-11-23 | Ciba-Geigy Corporation | Bis-benzoxazolyl-naphthalenes as optical brighteners |
| CH561242A5 (es) | 1971-08-10 | 1975-04-30 | Ciba Geigy Ag | |
| CH617809GA3 (es) * | 1975-10-10 | 1980-06-30 | ||
| US4110246A (en) * | 1976-05-13 | 1978-08-29 | Hoechst Aktiengesellschaft | Mixture of benzoxazole derivatives |
| DE2860900D1 (en) | 1977-08-22 | 1981-11-05 | Ici Plc | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them |
| DE3027479A1 (de) * | 1980-07-19 | 1982-03-04 | Hoechst Ag, 6000 Frankfurt | Mischungen von optischen aufhellern und deren verwendung |
| DE3046719C2 (de) | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| JPS615071A (ja) * | 1984-06-15 | 1986-01-10 | Fuji Photo Film Co Ltd | ベンゾオキサゾ−ル誘導体 |
| DE3617451A1 (de) * | 1986-05-23 | 1987-11-26 | Hoechst Ag | Sulfonat- oder sulfonamidgruppen-haltige bis-benzoxazolylnaphthaline, verfahren zu deren herstellung und deren verwendung |
| DE3762617D1 (de) | 1986-09-11 | 1990-06-13 | Nat Res Dev | Tamoxifenderivate. |
| JP2615805B2 (ja) | 1988-04-15 | 1997-06-04 | ミノルタ株式会社 | 感光体 |
| DE3819051A1 (de) * | 1988-06-04 | 1989-12-07 | Agfa Gevaert Ag | Farbfotografisches aufzeichnungsmaterial |
| DE69008521T2 (de) | 1989-03-07 | 1994-10-20 | Genentech Inc | Kovalente konjugate von lipiden und oligonukleotiden. |
| JPH0369292A (ja) | 1989-08-08 | 1991-03-25 | Sharp Corp | スロー再生における縦揺れ補正装置 |
| KR920702409A (ko) | 1989-10-24 | 1992-09-04 | 원본미기재 | 새로운 결합을 갖는 올리고뉴클레오티드 유사체 |
| ES2092080T3 (es) * | 1991-08-08 | 1996-11-16 | Ciba Geigy Ag | Colorantes, procedimiento para su obtencion y su utilizacion. |
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| JPH09507829A (ja) | 1993-03-19 | 1997-08-12 | ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | 増殖分化因子−８ |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| ES2157268T5 (es) * | 1994-02-24 | 2004-12-01 | SYMRISE GMBH & CO KG | Preparados cosmeticos y dermatologicos que contienen acidos fenilen-1,4-bisbencimidazolsulfonicos. |
| US6004719A (en) * | 1994-04-25 | 1999-12-21 | Polaroid Corporation | Imaging medium and process for producing an image |
| AU690302B2 (en) * | 1994-06-30 | 1998-04-23 | Dade Behring Inc. | Bioactive porous partition members |
| EP0767809B1 (en) * | 1994-06-30 | 2004-01-21 | Minnesota Mining And Manufacturing Company | Cure-indicating molding and coating composition |
| JPH0815917A (ja) | 1994-07-01 | 1996-01-19 | Mitsubishi Chem Corp | 静電荷像現像用帯電制御剤 |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| JPH08175992A (ja) | 1994-12-21 | 1996-07-09 | Sagami Chem Res Center | 神経成長因子産生促進剤および縮環型オキサゾール化合物 |
| JP3216458B2 (ja) | 1994-12-28 | 2001-10-09 | 富士レビオ株式会社 | アミド誘導体 |
| US5567843A (en) * | 1995-03-20 | 1996-10-22 | The Dow Chemical Company | Process for making 2-aryl benz (ox, thi, imid)azoles and 2-aminoaryl aminobenz(ox, thi, imid)azoles |
| US6222044B1 (en) * | 1995-03-20 | 2001-04-24 | The Dow Chemical Company | Process for making 2-aryl benz (ox, thi, imid) azoles and 2-aminoaryl aminobenz (ox, thi, imid) azoles |
| US5977101A (en) * | 1995-06-29 | 1999-11-02 | Smithkline Beecham Corporation | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity |
| JP3069292B2 (ja) | 1996-06-13 | 2000-07-24 | 株式会社分子バイオホトニクス研究所 | カテコール化合物及びバニリル化合物の蛍光検出用固相化試薬および検出方法 |
| US5645948A (en) * | 1996-08-20 | 1997-07-08 | Eastman Kodak Company | Blue organic electroluminescent devices |
| US5914213A (en) * | 1996-11-27 | 1999-06-22 | Polaroid Corporation | Process and composition for generation of acid |
| US6110638A (en) * | 1996-11-27 | 2000-08-29 | Polaroid Corporation | Process and composition for generation of acid |
| FR2757389B1 (fr) | 1996-12-24 | 1999-02-05 | Oreal | Composition cosmetique filtrante |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6177572B1 (en) * | 1997-08-20 | 2001-01-23 | Sepracor, Inc. | Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use |
| WO1999016761A1 (fr) | 1997-09-30 | 1999-04-08 | Mitsubishi Chemical Corporation | Derives heterocycliques oxygenes |
| JPH11171881A (ja) | 1997-09-30 | 1999-06-29 | Mitsubishi Chemical Corp | 含酸素複素環誘導体 |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| US6312822B1 (en) * | 1998-05-28 | 2001-11-06 | Eastman Chem Co | Dispersion aids for optical brighteners in polyolefins |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| US6436558B1 (en) * | 1998-08-07 | 2002-08-20 | Fuji Photo Film Co., Ltd. | Organic electroluminescence element |
| SE9804465D0 (sv) | 1998-12-22 | 1998-12-22 | Amersham Pharm Biotech Ab | A method for the removal/purification of serum albumins and means for use in the method |
| FR2789582B1 (fr) * | 1999-02-12 | 2001-05-04 | Oreal | Compositions photoprotectrices contenant un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle |
| FR2789581B1 (fr) * | 1999-02-12 | 2001-05-04 | Oreal | Compositions photoprotectrices contenant un derive de benzotriazole, un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle |
| AU4798000A (en) | 1999-04-09 | 2000-11-14 | Smithkline Beecham Corporation | Triarylimidazoles |
| AU4755600A (en) * | 1999-05-07 | 2000-11-21 | Basf Aktiengesellschaft | Benzohetero cyclylcyclo hexenones and their use as herbicides |
| JP2002544132A (ja) * | 1999-05-07 | 2002-12-24 | ビーエーエスエフ アクチェンゲゼルシャフト | 除草剤としての４−（３’，４’−ヘテロシクリルベンゾイル）ピラゾール |
| FR2794645B1 (fr) * | 1999-06-08 | 2001-08-10 | Oreal | Compositions photoprotectrices contenant un compose hydrocarbone bis-hydroxyphenylbenzotriazole et un compose a groupements benzoazolyle ou benzodiazolyle |
| WO2001005820A2 (en) | 1999-07-20 | 2001-01-25 | Pharmexa A/S | Method for down-regulating gdf-8 activity |
| JP2001039034A (ja) | 1999-08-03 | 2001-02-13 | Mitsui Chemicals Inc | 光記録媒体 |
| GB2353038A (en) | 1999-08-12 | 2001-02-14 | Eastman Chem Co | Polyolefin composition comprising non-migrating optical brightener |
| ATE289291T1 (de) * | 1999-09-24 | 2005-03-15 | Ono Pharmaceutical Co | Hydroxamsäurederivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven wirkstoff enthalten |
| ES2259617T3 (es) | 1999-11-05 | 2006-10-16 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Compuestos heterociclicos y su aplicacion como medicamentos. |
| US6565987B2 (en) * | 1999-11-12 | 2003-05-20 | Eastman Chemical Company | Non-exuding optically brightened polyolefin blends |
| EP1250357A4 (en) | 2000-01-18 | 2004-06-16 | Ovita Ltd | MYOSTATIN AND ITS MIMETIC |
| GB0003256D0 (en) | 2000-02-11 | 2000-04-05 | Darwin Discovery Ltd | Heterocyclic compounds and their therapeutic use |
| CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| JP2001261664A (ja) | 2000-03-15 | 2001-09-26 | Konica Corp | ハロゲン化銀写真感光材料、画像形成方法並びに化合物及びその合成方法 |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| US7361678B2 (en) * | 2002-03-05 | 2008-04-22 | Transtech Pharma, Inc. | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents |
| JP2002047278A (ja) | 2000-08-02 | 2002-02-12 | Fuji Photo Film Co Ltd | チオエーテル化合物の製造方法 |
| PT1334091E (pt) | 2000-08-24 | 2013-01-07 | Univ Pittsburgh | Derivados de tioflavina e seu uso no diagnóstico e terapia da doença de alzheimer |
| US6716413B1 (en) * | 2000-10-16 | 2004-04-06 | Mallinckrodt, Inc. | Indole compounds as tissue-specific exogenous optical agents |
| FR2816509B1 (fr) | 2000-11-15 | 2004-02-06 | Sod Conseils Rech Applic | Association d'inhibiteurs de calpaine et de piegeurs des formes reactives de l'oxygene |
| WO2002040468A1 (en) | 2000-11-16 | 2002-05-23 | Smithkline Beecham Corporation | Compounds |
| WO2002044189A1 (fr) * | 2000-11-30 | 2002-06-06 | Canon Kabushiki Kaisha | Element luminescent et afficheur |
| FR2818142B1 (fr) | 2000-12-18 | 2003-12-26 | Oreal | Compositions antisolaires a base d'un base melange synergetique de filtres et utilisations |
| GB0102668D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| DE10123711A1 (de) | 2001-05-15 | 2003-02-27 | Wolfgang Altmeyer | Verfahren zur Bestimmung der Herkunft biologischer Materialien |
| JP2003005356A (ja) | 2001-06-20 | 2003-01-08 | Fuji Photo Film Co Ltd | 電子線又はｘ線用ネガ型レジスト組成物 |
| US6702667B2 (en) | 2001-08-23 | 2004-03-09 | Igt | Apparatus for heating and/or cooling a beverage on a gaming apparatus |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| KR100438706B1 (ko) | 2001-12-10 | 2004-07-05 | 삼성전자주식회사 | 전력 절감 기능을 갖는 전력 공급 장치 및 방법 |
| CA2473740A1 (en) | 2002-01-18 | 2003-07-31 | David Solow-Cordero | Methods of treating conditions associated with an edg receptor |
| US20050261298A1 (en) * | 2002-01-18 | 2005-11-24 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
| US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| JP4294917B2 (ja) | 2002-07-02 | 2009-07-15 | 三井化学株式会社 | 光記録媒体およびオキサゾール化合物 |
| EP1547996A4 (en) * | 2002-08-30 | 2006-08-02 | Bf Res Inst Inc | DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES IN WHICH PRION PROTEIN IS ACCUMULATED, AND ANIMAL FEVERING FOR PRION PROTEIN |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| US7622592B2 (en) | 2002-11-01 | 2009-11-24 | Merck & Co., Inc. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
| WO2004058988A2 (en) | 2002-12-20 | 2004-07-15 | Amgen, Inc. | Binding agents which inhibit myostatin |
| WO2004069394A2 (en) | 2003-02-03 | 2004-08-19 | The Trustees Of Columbia University In The City Of New York | Synthetic method for direct arylation of heterocyclic arenes |
| JP2004250411A (ja) | 2003-02-21 | 2004-09-09 | Bf Kenkyusho:Kk | アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物 |
| EP1454627A1 (en) | 2003-03-06 | 2004-09-08 | MyoContract Ltd. | Alpha-Keto carbonyl calpain inhibitors |
| ES2887054T3 (es) | 2003-04-11 | 2021-12-21 | Ptc Therapeutics Inc | Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades |
| EP1620413A2 (en) | 2003-04-30 | 2006-02-01 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| JP2007516227A (ja) * | 2003-05-16 | 2007-06-21 | アンビット バイオサイエンシス コーポレーション | ピロール化合物およびその使用 |
| EP1635823A1 (en) * | 2003-05-20 | 2006-03-22 | TransTech Pharma Inc. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| BRPI0414313A (pt) * | 2003-09-11 | 2006-11-07 | Kemia Inc | inibidores de citocinas |
| US7527916B2 (en) * | 2003-09-22 | 2009-05-05 | Agfa Graphics, N.V. | Photopolymerizable composition |
| FR2863268B1 (fr) | 2003-12-09 | 2006-02-24 | Sod Conseils Rech Applic | Nouveaux derives du 2-hydroxytetrahydrofuranne et leur application a titre de medicaments |
| US7097888B2 (en) * | 2003-12-15 | 2006-08-29 | Eastman Kodak Company | Aligned liquid crystal layer containing azolium salts and process for increasing the tilt |
| US7592373B2 (en) * | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
| CA2555313A1 (en) * | 2004-02-06 | 2005-08-18 | Insight Biopharmaceuticals Ltd | Heparanase inhibitors and uses thereof |
| JP2007526337A (ja) | 2004-03-02 | 2007-09-13 | アクセルロン ファーマ インコーポレーテッド | Ａｌｋ７およびミオスタチン阻害剤ならびにその使用 |
| ES2384176T3 (es) | 2004-03-23 | 2012-07-02 | Eli Lilly & Company | Anticuerpos anti-miostatina |
| WO2005124563A2 (en) | 2004-06-12 | 2005-12-29 | Ceptor Corporation | Compounds and kits for treating muscle disorders and methods of use thereof |
| MY144903A (en) * | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
| WO2006012627A2 (en) | 2004-07-23 | 2006-02-02 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| MX2007001118A (es) | 2004-07-29 | 2007-03-15 | Schering Plough Ltd | Uso de inhibidores cinasa semejante a activina 5 para modular o inhibir la actividad de miostatina llevando a acrecion incrementada del tejido magro en los animales. |
| EP1776086A2 (en) | 2004-08-09 | 2007-04-25 | Ciba Specialty Chemicals Holding Inc. | Use of fluorescent whitening agents as antimicrobials |
| CN101006159B (zh) * | 2004-08-19 | 2011-11-09 | Lg化学株式会社 | 包括缓冲层的有机发光器件及其制备方法 |
| WO2006044456A1 (en) | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| BRPI0406040B1 (pt) | 2004-10-21 | 2018-09-11 | Universidade Federal Do Rio De Janeiro - Ufrj | compostos capazes de absorver radiação ultravioleta, composições contendo os mesmos e processos para sua preparação |
| WO2006051410A1 (en) | 2004-11-15 | 2006-05-18 | Pfizer Inc. | Azabenzoxazoles for the treatment of cns disorders |
| GB0426154D0 (en) | 2004-11-29 | 2004-12-29 | European Molecular Biology Lab Embl | IGF-1 novel peptides |
| US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| WO2006091862A2 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Cytokine inhibitors and their use in therapy |
| US7998974B2 (en) | 2005-03-03 | 2011-08-16 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| CA2599989A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
| US20060223849A1 (en) * | 2005-03-14 | 2006-10-05 | Mjalli Adnan M | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors |
| DK1874306T3 (da) | 2005-04-08 | 2012-10-01 | Ptc Therapeutics Inc | Sammensætninger af en oralt aktiv 1,2,4-oxadiazol til nonsens-mutationssuppressionsterapi |
| EA015534B1 (ru) | 2005-04-25 | 2011-08-30 | Пфайзер Инк. | Антитела к миостатину и способы их применения |
| WO2006124780A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase |
| CA2617557A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
| FR2889700B1 (fr) | 2005-08-11 | 2012-11-23 | Synthinnove Lab | Marqueurs, leur procede de fabrication et leurs applications |
| JP2007086165A (ja) * | 2005-09-20 | 2007-04-05 | Fujifilm Corp | 感光性組成物、これを用いた平版印刷版原版及び画像記録方法 |
| WO2007045761A1 (fr) | 2005-10-21 | 2007-04-26 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derives d'amidine et leurs applications a titre de medicament |
| KR100890862B1 (ko) | 2005-11-07 | 2009-03-27 | 주식회사 엘지화학 | 유기 발광 소자 및 이의 제조 방법 |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| ES2455166T3 (es) * | 2005-12-02 | 2014-04-14 | Sachem, Inc. | Procedimiento de cromatografía de desplazamiento de intercambio aniónico |
| KR101213485B1 (ko) * | 2006-01-27 | 2012-12-18 | 삼성디스플레이 주식회사 | 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자 |
| KR101213486B1 (ko) * | 2006-02-02 | 2012-12-20 | 삼성디스플레이 주식회사 | 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자 |
| KR101472248B1 (ko) | 2006-02-10 | 2014-12-16 | 서미트 코포레이션 피엘씨 | 뒤시엔느 근이영양증의 치료 |
| WO2007096362A1 (en) | 2006-02-21 | 2007-08-30 | Trigen Limited | Heterocyclic compounds and their use in the treatment of cardiovascular disease |
| JP4649645B2 (ja) | 2006-03-10 | 2011-03-16 | 独立行政法人科学技術振興機構 | 光学活性アルコール化合物の製法 |
| KR101325062B1 (ko) * | 2006-05-19 | 2013-11-05 | 삼성디스플레이 주식회사 | 발광 이종 핵 구리-이리듐 착체 및 이를 이용한 유기 전계발광 소자 |
| AU2007257959A1 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| US20070287344A1 (en) * | 2006-06-12 | 2007-12-13 | Hiroshi Ohara | Fabric Construction Specifically For Damper |
| RS55735B1 (sr) | 2007-08-03 | 2017-07-31 | Summit (Oxford) Ltd | Kombinacije lekova za lečenje dišenove mišićne distrofije |
-
2008
- 2008-08-01 RS RS20170207A patent/RS55735B1/sr unknown
- 2008-08-01 PL PL08788620T patent/PL2170396T3/pl unknown
- 2008-08-01 MX MX2009012558A patent/MX2009012558A/es not_active Application Discontinuation
- 2008-08-01 US US12/600,242 patent/US8501713B2/en not_active Expired - Fee Related
- 2008-08-01 ES ES08788620.6T patent/ES2617957T3/es active Active
- 2008-08-01 HU HUE08788620A patent/HUE033195T2/en unknown
- 2008-08-01 CN CN200880015923A patent/CN101678107A/zh active Pending
- 2008-08-01 SI SI200831771A patent/SI2170396T1/sl unknown
- 2008-08-01 TW TW097129385A patent/TW200911237A/zh unknown
- 2008-08-01 CA CA2685540A patent/CA2685540C/en not_active Expired - Fee Related
- 2008-08-01 WO PCT/GB2008/050648 patent/WO2009019504A1/en not_active Ceased
- 2008-08-01 EP EP08788620.6A patent/EP2170396B1/en active Active
- 2008-08-01 JP JP2010518750A patent/JP2010535708A/ja active Pending
- 2008-08-01 PE PE2008001295A patent/PE20090510A1/es not_active Application Discontinuation
- 2008-08-01 LT LTEP08788620.6T patent/LT2170396T/lt unknown
- 2008-08-01 HR HRP20170313TT patent/HRP20170313T1/hr unknown
- 2008-08-01 AR ARP080103355A patent/AR068332A1/es unknown
- 2008-08-01 EP EP16203981.2A patent/EP3251694A1/en not_active Withdrawn
- 2008-08-01 BR BRPI0811317-3A2A patent/BRPI0811317A2/pt not_active Application Discontinuation
- 2008-08-01 AU AU2008285289A patent/AU2008285289A1/en not_active Abandoned
- 2008-08-01 CL CL2008002279A patent/CL2008002279A1/es unknown
- 2008-08-01 DK DK08788620.6T patent/DK2170396T3/en active
- 2008-08-01 PT PT87886206T patent/PT2170396T/pt unknown
-
2013
- 2013-06-07 US US13/912,375 patent/US20140011782A1/en not_active Abandoned
-
2017
- 2017-03-02 CY CY20171100278T patent/CY1118700T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2170396T3 (pl) | 2017-07-31 |
| SI2170396T1 (sl) | 2017-04-26 |
| LT2170396T (lt) | 2017-03-10 |
| BRPI0811317A2 (pt) | 2015-01-27 |
| TW200911237A (en) | 2009-03-16 |
| CA2685540A1 (en) | 2009-02-12 |
| EP2170396B1 (en) | 2016-12-21 |
| AU2008285289A1 (en) | 2009-02-12 |
| PT2170396T (pt) | 2017-03-31 |
| PE20090510A1 (es) | 2009-05-22 |
| HUE033195T2 (en) | 2017-11-28 |
| CA2685540C (en) | 2018-10-16 |
| HRP20170313T1 (hr) | 2017-04-21 |
| MX2009012558A (es) | 2010-04-21 |
| CY1118700T1 (el) | 2017-07-12 |
| EP3251694A1 (en) | 2017-12-06 |
| US20140011782A1 (en) | 2014-01-09 |
| WO2009019504A1 (en) | 2009-02-12 |
| RS55735B1 (sr) | 2017-07-31 |
| US20110195932A1 (en) | 2011-08-11 |
| JP2010535708A (ja) | 2010-11-25 |
| ES2617957T3 (es) | 2017-06-20 |
| CL2008002279A1 (es) | 2009-11-27 |
| CN101678107A (zh) | 2010-03-24 |
| DK2170396T3 (en) | 2017-03-13 |
| EP2170396A1 (en) | 2010-04-07 |
| US8501713B2 (en) | 2013-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068332A1 (es) | Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne | |
| CY1123645T1 (el) | Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα | |
| AR038823A1 (es) | Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c | |
| AR110270A1 (es) | Preparación de complejos sólidos de ciclodextrina para la administración de ingredientes farmacéuticos activos oftálmicos | |
| AR070079A1 (es) | Derivados de morfolino pirimidina usados en enfermedades relacionadas con mtor quinasa y/o p13k | |
| CY1122870T1 (el) | Νεα πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
| CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
| AR108396A1 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| TW200505453A (en) | Non-nucleoside reverse transcriptase inhibitors | |
| MX2024010631A (es) | Derivados ciclicos de panteteina y usos de los mismos | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| CY1124528T1 (el) | Ν-υποκατεστημενα παραγωγα ινδολης | |
| BR112017026224A2 (pt) | moduladores de ror gama (rory) | |
| PH12022550018A1 (en) | 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents | |
| CY1111442T1 (el) | Ενωσεις πιπεριδινης και χρησεις αυτων | |
| CO2022005999A2 (es) | Inhibidores del factor d del complemento para administración oral | |
| AR045156A1 (es) | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
| CN106999540A (zh) | 组合疗法 | |
| AR096729A1 (es) | Derivados terapéuticamente activos de estratien-tiazol | |
| AR022413A1 (es) | Utilizacion de derivados de piridazino(4,5-b)indol-1-acetamida, para la preparacion de medicamentos destinados a las enfermedades del sistema nerviosocentral | |
| JP2019513828A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |